Image
Figure Caption

Figure 6—figure supplement 1. Pharmacological blockade of the AB<sup>long</sup>-Prp-MgluR5-Fyn Kinase signalling cascade prevents reductions in waking activity.

(A) Representative traces of waking activity after Aβlong versus Aβrev injections in wild type larvae in the absence (left) or presence (right) of the Aβ-Prp binding disruptor, Chicago Sky Blue 6B (3 nM). The data are from the same injections as in Figure 6B. Ribbons represent ± SEM. Light and dark bars indicate the lights ON and lights OFF periods, respectively. (B) The change in normalized waking activity induced by Aβlong versus Aβrev control injections in the absence or presence of 3 nM Chicago Sky Blue 6B. Each dot represents a single larva and error bars indicate ± SEM. The mean difference effect size and 95% confidence interval is plotted at the bottom. N = the number of larvae in each group. **p≤0.01, Kruskal-Wallis, Tukey-Kramer post hoc. (C) Representative traces of sleep behavior after Aβlong versus Aβrev injections (left) in the presence of the mGluR5 inhibitor, MPEP (5 μM) and (right) Src-kinase inhibitor, saracatinib (300 nM). Ribbons represent ± SEM. The data are from the same injections as in Figure 6D. (D) The change in sleep induced by Aβlong relative to Aβrev control injections in the presence of MPEP (5 μM) and (300 nM) saracatinib. *p≤0.05, **p≤0.01, Kruskal-Wallis, Tukey-Kramer post hoc.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Elife